CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop novel molecules for cancer immunotherapy that can enhance immune response while minimizing side effects. By targeting both myeloid and lymphoid immune cells, it seeks to create more effective treatments for a broader range of cancers.
Immunotherapy holds great promise for the curative treatment of millions of cancer patients, with a market size of over 100 billion USD today, which is expected to at least double in the next decade.
Cancer immunotherapies are designed either to promote anti-tumor immune activity in the tumor microenvironment (TME), via molecules such as cytokines and antibodies, or to inhibit negative T cell signals induced by cancer and antigen-presenting cells (APCs) in the TME, an approach known as immune ch…
WEIZMANN INSTITUTE OF SCIENCE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
